A study of JMKX005425 for certain advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called JMKX005425 for people with advanced solid tumors that have a specific genetic feature called MSI-H or dMMR. If you have this feature and your cancer has not responded to other treatments, this study may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must be tested and show a specific genetic feature called MSI-H or dMMR.
- You must have at least one tumor that can be measured on scans.
- You should expect to live at least 12 more weeks.
- Your organs must be working well enough, including your kidneys, liver, and bone marrow.
- Any side effects from previous cancer treatments must have improved enough.
- You cannot have had another cancer in the last 3 years (except some treated earlier ones).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental pill (FS-207) for people with advanced solid tumors that have a specific genetic marker called MSI-H (high microsatellite instability) or dMMR. If you have already had immunotherapy that didn't work, this drug might help by attacking cancer cells in a new way.
This study tests a new experimental drug called MK-6204 (also known as SKB535) to see if it is safe and effective for people with certain advanced cancers that have not responded to standard treatments. The drug is given by injection and may help shrink tumors or slow their growth.
This Phase 2 trial tests KN035 in people with advanced or spread-out tumors that have specific genetic markers (MSI-H or dMMR). If you qualify, the study team will look at how well the drug works and how it affects side effects in that group.
This trial tests an experimental drug called KM602 for people with advanced solid tumors that have stopped responding to standard treatments, particularly melanoma and non-small cell lung cancer. It aims to see if the drug is safe and effective in shrinking or controlling tumors.
This trial tests a new drug called JSKN027 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this drug is safe and if it can shrink tumors or slow their growth.
This trial tests an experimental drug called QLS1317 for people with advanced solid tumors that have a specific genetic marker (MSI-H or dMMR) and have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.